Testing an oral medicine for moderate to severe hidradenitis
Treatments studied
Part of Infections, Skin clinical trials.
This Phase 3 study tests upadacitinib taken by mouth to reduce hidradenitis suppurativa (HS) symptoms and disease activity, and to track side effects. It is for people who have already tried anti-TNF treatments and still had inadequate response or couldn’t tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hidradenitis suppurativa for at least 6 months
- You tried an anti-TNF medicine for HS for at least 12 weeks (or another biologic for at least 16 weeks), but it didn’t work or you couldn’t tolerate it
- Your baseline HS exam shows at least 5 abscesses and inflammatory bumps (AN count)
- You have HS lesions in at least 2 different body areas, and at least one area is Hurley stage II or higher
- Your draining fistula count at baseline is 20 or less
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This study tests an oral medicine called ritlecitinib for moderate to severe hidradenitis suppurativa (HS) in adults who haven't responded well to antibiotics. The goal is to see if it can reduce painful red lumps and improve quality of life.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.